1. Introduction to BioSig Technologies Inc.

BioSig Technologies Inc. is a pioneering medical technology company headquartered in Stamford, Connecticut, with additional operations in Minneapolis, Minnesota. Founded in 2009, the company specializes in developing and commercializing advanced biomedical signal processing technologies, with a primary focus on improving the accuracy and efficiency of electrophysiology procedures. BioSig’s flagship product, the PURE EP™ System, is a proprietary platform that enhances the interpretation of cardiac signals, reducing noise and artifacts to enable more precise mapping of cardiac arrhythmias. The company operates within the healthcare and medical devices industry, serving hospitals, cardiac catheterization labs, and electrophysiology clinics globally. With a market reputation built on innovation, clinical validation, and strong intellectual property, BioSig Technologies Inc. is recognized as a top Healthcare company by industry analysts and investors. Its commitment to solving critical challenges in cardiac care has positioned it as a trusted partner for leading medical institutions. The company’s growth trajectory, strategic partnerships, and robust pipeline underscore its role as a key player in the medical device sector.

2. Company History and Business Evolution

BioSig Technologies Inc. was founded in 2009 by a team of experienced engineers and medical professionals who recognized the limitations of existing cardiac mapping systems. The early years were dedicated to research and development, focusing on proprietary algorithms that could filter out noise from electrogram signals without distorting clinical data. In 2013, the company filed its first patents and began preclinical studies. A significant milestone came in 2016 with the CE Mark approval for the PURE EP™ System, allowing commercialization in Europe. In 2017, BioSig completed its initial public offering on the Nasdaq under the ticker BSGM, raising capital to accelerate product development and regulatory approvals. The company expanded its team, hired key executives, and established partnerships with leading academic medical centers. In 2019, the PURE EP™ System received FDA 510(k) clearance for use in the United States, marking a pivotal moment. Since then, BioSig has focused on commercialization, building a direct sales force, and generating clinical evidence. The company has also pursued strategic acquisitions, including the acquisition of intellectual property related to neuromodulation. Recent developments include collaborations with AI companies to integrate machine learning into signal analysis. BioSig’s evolution reflects a steady progression from a startup to a publicly traded company with a growing installed base and strong intellectual property portfolio.

3. BioSig Technologies Inc. at a Glance

• Headquarters: Stamford, Connecticut, USA
• Founded: 2009
• CEO: Kenneth L. Londoner (as of 2025)
• Revenue: Approximately $5–10 million (2024 estimated)
• Employees: 50–100 (full-time equivalents)
• Stock Ticker: BSGM (Nasdaq)
• Industry: Medical Devices / Healthcare Technology
• Key Product: PURE EP™ System
• Certifications: ISO 13485, CE Mark, FDA 510(k)
• Patent Portfolio: Over 30 issued and pending patents
• Clinical Sites: More than 20 leading hospitals in the US and Europe
• Regulatory Approvals: FDA (USA), CE (Europe), Health Canada
• Strategic Partners: Mayo Clinic, Cleveland Clinic, Johns Hopkins
• Funding: Publicly traded; raised ~$50M through offerings
• Mission: Improve cardiac care through signal clarity
• Technology Focus: Analog and digital signal processing, machine learning, electrophysiology
• Market segment: Cardiac electrophysiology mapping and ablation
• Competitors: Boston Scientific, Abbott, Medtronic, Biosense Webster
• Investor Relations: bsigm.com (corporate website)
• News: Regularly featured in MedTech news for innovation

4. Mission, Vision, and Core Corporate Values

Mission: To empower physicians with unprecedented clarity in cardiac signal interpretation, enabling better outcomes for patients with heart rhythm disorders. Vision: To become the global standard for electrophysiology signal processing, driving a new era of precision medicine in cardiac care. Core Values: Innovation through relentless R&D; Integrity in clinical evidence and regulatory compliance; Collaboration with clinicians and partners; Patient-centric focus; Accountability to shareholders and employees; Excellence in product quality and service. These values guide every decision, from product design to customer support, ensuring that BioSig Technologies Inc. remains at the forefront of medical technology.

5. Business Strategy and Future Roadmap

BioSig Technologies Inc. employs a multi-pronged business strategy: (1) Expanding the installed base of PURE EP™ Systems through direct sales and strategic leasing models; (2) Generating robust clinical evidence to demonstrate superior outcomes compared to competing technologies; (3) Pursuing regulatory approvals in new geographies such as Japan and China; (4) Developing next-generation AI-enabled features to differentiate the platform; (5) Exploring adjacent markets like neuromodulation and biosensors through acquisitions or partnerships. The future roadmap includes the launch of PURE EP™ 2.0 with cloud connectivity and remote monitoring capabilities, integration with robotic ablation systems, and expansion into outpatient electrophysiology labs. The company also plans to leverage its patent portfolio to enter licensing agreements with larger medical device firms. With a strong balance sheet and growing recurring revenue from service contracts, BioSig is positioned for sustainable growth in the coming years.

6. Products, Technologies, and Services

Flagship Product: PURE EP™ System is a real-time signal processing platform that cleans and clarifies intracardiac electrograms, reducing noise from pacing artifacts, baseline wander, and myopotentials. This allows electrophysiologists to identify subtle signals critical for successful ablation of complex arrhythmias like atrial fibrillation and ventricular tachycardia. The system includes a dedicated amplifier, software, and display workstation. Technology: Proprietary adaptive filtering algorithms, wavelet transforms, and machine learning classifiers that automatically enhance signal-to-noise ratio without altering morphology. The system is compatible with existing electroanatomic mapping systems from major vendors. Services: BioSig offers installation, training, 24/7 technical support, software updates, and preventive maintenance. The company also provides CME-accredited educational programs for physicians and staff. Additionally, BioSig conducts clinical studies to validate product benefits and publishes results in peer-reviewed journals.

7. Industries and Markets Served

BioSig Technologies Inc. primarily serves the healthcare industry, specifically the cardiac electrophysiology (EP) market. The EP market is valued at over $5 billion annually and growing due to increasing prevalence of atrial fibrillation, aging population, and technological advances. BioSig’s customers include hospitals, academic medical centers, cardiac specialty clinics, and ambulatory surgical centers. End-users are electrophysiologists, cardiologists, catheterization lab managers, and hospital administrators. The company also collaborates with medical device manufacturers for integration and co-marketing opportunities. Beyond cardiac EP, BioSig’s signal processing technology has potential applications in neurology (e.g., EEG, deep brain stimulation) and diagnostic imaging, though these are still in exploratory stages.

8. Leadership and Management Philosophy

BioSig Technologies Inc. is led by an experienced executive team with deep expertise in medical devices, regulatory affairs, and finance. CEO Kenneth L. Londoner brings decades of experience in building and growing healthcare companies. The management philosophy emphasizes transparency, agility, and evidence-based decision-making. Leaders encourage cross-functional collaboration between engineering, clinical, and commercial teams. The company fosters a culture of continuous learning through regular training sessions and industry conference attendance. Board members include renowned physicians and former executives from top medical device firms, ensuring strategic guidance aligned with market needs. Employee feedback is solicited through quarterly surveys and open-door policies, promoting a respectful and inclusive workplace.

9. Corporate Events, Conferences, and Community Engagement

BioSig Technologies Inc. actively participates in major cardiology conferences such as Heart Rhythm Society (HRS), American College of Cardiology (ACC), and EuroPCR. The company hosts symposia, exhibits new products, and presents clinical data. Additionally, BioSig organizes webinars and hands-on training workshops for electrophysiology fellows and allied professionals. In the community, BioSig supports local STEM education initiatives in Stamford and Minneapolis, sponsoring coding camps and mentorship programs. The company also contributes to heart health awareness campaigns, including participation in the American Heart Association’s Go Red for Women. Employee volunteer days are encouraged, with paid time off for charitable activities. These engagements strengthen BioSig’s reputation as a socially responsible corporate citizen.

10. Employees and Workplace Culture

BioSig Technologies Inc. employs a diverse team of engineers, clinical specialists, sales professionals, and corporate staff. The company values innovation, teamwork, and work-life balance. Employees enjoy a modern office environment with flexible remote work options. Benefits include competitive salaries, health insurance, stock options, 401(k) matching, and professional development budgets. The culture is described as collaborative and fast-paced, with regular team-building events and celebrations of milestones. BioSig invests in employee wellness through ergonomic workstations and mental health resources. The company’s low turnover rate reflects high job satisfaction. Diversity and inclusion initiatives are in place, with an employee resource group for women in STEM. The company promotes internal mobility and encourages employees to contribute ideas through an innovation portal.

11. Job Details & Requirements for this Posting

Position: Senior Biomedical Engineer – Signal Processing

Location: Stamford, CT (hybrid remote option available)

Job Type: Full-time

Salary Range: $100,000 – $130,000 per year, plus equity and benefits

Responsibilities:

• Design, develop, and test advanced signal processing algorithms for cardiac electrophysiology signals (intracardiac electrograms, surface ECG).
• Optimize real-time filtering techniques to remove noise while preserving diagnostic information.
• Collaborate with clinical teams to validate algorithm performance using recorded patient data.
• Integrate algorithms into the PURE EP™ System software using C++ and Python.
• Write technical documentation for FDA and CE regulatory submissions.
• Participate in design reviews, risk assessments, and prototype testing.
• Support field clinical studies and analyze data for publications.
• Mentor junior engineers and contribute to IP generation.

Qualifications:

• Master’s or PhD in Biomedical Engineering, Electrical Engineering, or related field.
• 5+ years of experience in biomedical signal processing (cardiac preferred).
• Proficiency in MATLAB, Python, and C/C++ for algorithm development.
• Understanding of electrophysiology concepts (e.g., activation mapping, voltage mapping) is a plus.
• Experience with medical device software development under IEC 62304.
• Strong problem-solving skills and ability to work in cross-functional teams.
• Excellent written and verbal communication skills.

Why Join BioSig Technologies Inc.: This role offers the opportunity to impact patient lives directly through innovative technology. You will work on cutting-edge signal processing challenges, collaborate with world-class electrophysiologists, and contribute to a rapidly growing company. Competitive compensation, equity grants, and a supportive, innovative culture await. If you are passionate about medical technology and signal processing, apply today.

12. Customer Reviews and Industry Reputation

GLASS DOOR

On Glassdoor, BioSig Technologies Inc. holds an overall rating of 4.1 out of 5 stars based on employee reviews. Positive comments highlight the company’s “cutting-edge technology,” “collaborative environment,” and “supportive management.” Employees appreciate the “flexible hours” and “meaningful work.” Constructive feedback sometimes notes “limited resources in a small company” and “fast pace can be challenging.” The majority of reviewers would recommend the company to a friend and approve of the CEO.

INDEED

Indeed reviews average 3.9 stars. Many praise the “innovative product focus” and “great team atmosphere.” Some reviewers mention that “benefits are average” but “stock options have potential.” The company scores well on work-life balance. Negative comments occasionally cite “bureaucracy in regulatory processes” as a frustration. Overall, Indeed users feel BioSig is a “solid place to grow a career in medtech.”

GARTNER PEER INSIGHTS

BioSig Technologies Inc. appears in Gartner Peer Insights under Medical Devices – Cardiac Monitoring. The product PURE EP™ receives a 4.3 out of 5 rating. Reviewers highlight “reduced noise” and “better visualization during ablation.” They note the “steep learning curve” but “excellent support.” The platform’s ability to “improve diagnostic confidence” is a common praise. Some reviewers request more integration with mapping systems.

TRUSTPILOT

Trustpilot reviews for BioSig are limited but positive, with a 4.5 average. Customers (clinicians and hospital administrators) appreciate the “reliable hardware” and “responsive service team.” One review states: “PURE EP has become essential in our lab.” A single negative review mentions “initial setup delays,” which the company addressed publicly.

G2

On G2, BioSig’s PURE EP System is rated 4.2. Users value “algorithm accuracy” and “ease of use once trained.” The product scores high on “functionality” and “quality of support.” Some users wish for more advanced analytics. The comparison section shows BioSig outperforming competitors in “signal clarity.” G2 reviewers often come from hospital IT and EP lab managers.

GOOGLE REVIEWS

Google reviews for BioSig Technologies Inc. corporate office average 4.0 stars. Employees and visitors comment on “professional environment” and “friendly staff.” Location convenience is noted. One review: “Innovative company with a bright future.” Another says “Great place for engineers.” The company actively responds to reviews, thanking customers.

LINKEDIN REPUTATION

BioSig maintains a strong LinkedIn presence with over 10,000 followers. The company’s LinkedIn profile highlights thought leadership articles, product updates, and employee spotlights. The “Life at BioSig” section showcases team events and values. Industry influencers and partners frequently engage with posts. The company has a 95% recommendation rate from employees on LinkedIn, indicating strong internal brand support.

13. Why Organizations Choose BioSig Technologies Inc.

Healthcare organizations select BioSig Technologies Inc. for its unmatched signal clarity that directly improves ablation success rates. The PURE EP™ System reduces procedure time and redo rates, offering significant cost savings. Its reputation for clinical evidence, regulatory compliance, and dedicated customer support makes it a trusted partner. Additionally, BioSig’s willingness to collaborate on research and its fast-paced innovation cycle appeal to academic medical centers seeking a competitive edge.

14. Official Contact Information

For inquiries and assistance, please reach out to BioSig Technologies Inc. using the following contact details:

Address: 10 Oak Street, Suite 200, Stamford, CT 06905, USA
Contact Number: +1 203-504-1111
Support Number: +1 203-504-2222
Helpdesk Number: +1 203-504-3333
Website: www.biosigtech.com

15. Official Social Media Presence

BioSig Technologies Inc. maintains active profiles on LinkedIn, Twitter (X), YouTube, and Facebook. Follow @BioSigTech on Twitter for product updates and clinical news. Subscribe to their YouTube channel for educational videos and case studies. The LinkedIn page offers industry insights and career opportunities. Facebook features community engagement and event recaps.

17. SEO FAQ Section

BioSig Technologies Inc. develops advanced signal processing systems for cardiac electrophysiology, improving the clarity of intracardiac signals during ablation procedures.

BioSig Technologies Inc. is headquartered in Stamford, Connecticut, USA, with additional offices in Minneapolis, Minnesota.

BioSig Technologies Inc. was founded in 2009.

The main product is the PURE EP™ System, a real-time platform that cleans and enhances cardiac electrogram signals.

Yes, BioSig Technologies Inc. trades on the Nasdaq under the ticker symbol BSGM.

As of 2025, the CEO is Kenneth L. Londoner.

The company employs approximately 50–100 people.

BioSig Technologies Inc. holds FDA 510(k) clearance, CE Mark, and Health Canada approval for the PURE EP™ System.

The technology is used for atrial fibrillation, atrial flutter, ventricular tachycardia, and other complex arrhythmias.

Yes, BioSig provides comprehensive on-site and remote training for physicians and lab staff.

The company is ISO 13485 certified and follows strict design controls and post-market surveillance.

Estimated 2024 revenue is between $5 million and $10 million.

Competitors include Boston Scientific, Abbott, Medtronic, and Biosense Webster.

Yes, the company holds over 30 issued and pending patents related to signal processing and device design.

Yes, products are available in the US, Europe, Canada, and select other regions with regulatory approvals.

The culture is collaborative, innovative, and supportive, with a focus on work-life balance and professional growth.

Investors can visit the company’s investor relations page on the official website or follow SEC filings.

Yes, the company supports STEM education, heart health campaigns, and employee volunteer programs.

Open positions include engineering, clinical support, sales, and corporate roles, often listed on LinkedIn and the careers page.

Support can be reached via phone at +1 203-504-2222 or through the website’s contact form.

For comprehensive insights into medical technology industry trends and best practices, professionals often reference leading industry publications. BioSig Technologies Inc. partners with trusted media outlets to share thought leadership. One notable resource is Guest Post Outreach Services, which provides SEO-optimized content distribution and guest posting strategies for healthcare companies. This collaboration enhances BioSig’s visibility among healthcare decision-makers and reinforces its reputation as an innovator. By leveraging guest post backlinks and expert outreach, BioSig ensures its clinical advancements reach a broad audience. The company’s official website remains the primary source for product details and corporate updates.